1 completed, 1 not yet recruiting, 1 recruiting, 1 withdrawn. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 1, Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 1, Not yet recruiting 1 |
Follow Spermine Synthase: new trials by email Literature Review of Spermine Synthase trials Research Report on Spermine Synthase
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Investigate Small Mobile Stem Cells (SMS) in Moderate to Severe Chronic Obstructive Pulmonary Disease Stem cells - Chronic Obstructive Lung Disease | Phase 1 / Phase 2 | Not yet recruiting | SMSbiotech | 125 | 2026-10-01 | 2026-10-13 |
| Investigation of Small Mobile Stem Cells (SMS Cells) in Participants With Chronic Obstructive Pulmonary Disease (COPD). Stem cells - Chronic Obstructive Lung Disease | Phase 1 | Recruiting | SMSbiotech | 18 | 2025-06-13 | 2026-08-11 |
| Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Indoximod, Temozolomide, Bevacizumab - Glioblastoma Multiforme, Glioma | Phase 1 / Phase 2 | Completed | NewLink Genetics Corporation | 160 | 2014-03-01 | 2024-03-27 |
| Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases Vemurafenib, Whole-brain radiation therapy (WBRT), Radiosurgery (SRS) - Recurrent Melanoma, Stage IV Melanoma | Phase 1 | Withdrawn | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2025-05-02 |
Brain Neoplasms (2) · Pulmonary Disease, Chronic Obstructive (2) · Glioblastoma (1) · Glioma (1) · Gliosarcoma (1) · Melanoma (1)
SMSbiotech (2) · NewLink Genetics Corporation (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1)
United States (2) · Australia (1)
Trishul Siddharthan, Medical Doctor (1) · Wenyin Shi, MD, PhD (1)